中國China Patent OfficeCNIPAPatent LawUpdates and Changes
2023年11月10日

Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved

by
王怡瑾女士
車李曉芸女士

On November 3rd, 2023, the Premier of the State Council, Li Qiang, chaired a regular meeting where the "Implementation Regulations of the Patent Law of the People's Republic of China (Revised Draft)" was reviewed and approved. This is great news, as we have been waiting quite some time for these Regulations (Rules) to be approved (see our previous article summarizing the draft Implementation Rules). Considering the 4th Amendment of the new Chinese Patent Law was passed in October 2020, we have certainly been waiting a long time for more details about how this law will be implemented.

This document is not publicly available yet. However, the announcement provides a summary of key highlights:

Key Highlights:

  • China will continue to enhance protection of IP rights, with a goal of further refining the patent application and examination systems to improve China’s standards in patent innovation, application, protection, management, and related services.
  • China will continue efforts to strengthen alignment with relevant international treaties.
  • The Regulations affirm that the patent law plays a pivotal role in promoting technological innovation and the development of new industries and markets.
  • China will initiate multiple forms of public awareness campaigns on IP Rights to foster a legal environment that supports and safeguards innovation.

These high level statements reflect China’s overarching goals for strengthening both IP protection as well as public awareness of IP protection in China. We look forward to seeing the details of the Regulations.

As always, we keep an eye out for updates such as these and will inform you as soon as more details come out. 

其他文章

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

2025年2月4日
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]

First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing

2023年3月8日
What does an invention “completed” in China mean? China and the US are similar in that both countries highly value national security, and thus have rules regulating the exportation of technology and information from within their borders. This includes new inventions that arise from within their respective borders. As such, both governments require inventors who […]

China Forges Ahead with Draft Measures for New Patent Linkage System

2020年10月19日
Update! The finalized Implementation Measures are now out. You can read the details here: Breaking: China Released New Implementation Measures for the New Patent Linkage System Last month September 11, 2020, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) jointly issued a draft set of measures for public opinion […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

我們過去活動

Top crossarrow-right